A new FDA-approved product with the potential to triple weight loss in obesity patients should be a huge win for the company.
News & Analysis: Novo Nordisk
This stock could be a great addition to any long-term portfolio.
Which diabetes drug maker will win this photo finish for investors?
NVO earnings call for the period ending March 31, 2021.
Considering business quality is the best way to earn growing payouts over time.
NVO earnings call for the period ending December 31, 2020.
One metric shows that decades of dominance treating diabetes has created unrivaled profitability.
NVO earnings call for the period ending September 30, 2020.
DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.
NVO earnings call for the period ending June 30, 2020.